| Literature DB >> 16313339 |
Sakae Tanaka1, Kozo Nakamura, Naoyuki Takahasi, Tatsuo Suda.
Abstract
Osteoclasts are primary cells for physiological and pathological bone resorption, and receptor activator of nuclear factor-kappaB ligand (RANKL) is critically involved in the differentiation, activation, and survival of these cells. Recently, therapeutics for pathological bone destruction targeting RANKL pathways has attracted a great deal of attention. Herein, we review the recent advances in the research on osteoclast biology and discuss the advantages and disadvantages of anti-RANKL therapies.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16313339 DOI: 10.1111/j.0105-2896.2005.00327.x
Source DB: PubMed Journal: Immunol Rev ISSN: 0105-2896 Impact factor: 12.988